Curis (CRIS) Competitors $1.84 0.00 (0.00%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$1.81 -0.03 (-1.85%) As of 07/25/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRIS vs. FBIO, SABS, BOLT, AMGN, GILD, VRTX, REGN, ALNY, BIIB, and UTHRShould you be buying Curis stock or one of its competitors? The main competitors of Curis include Fortress Biotech (FBIO), SAB Biotherapeutics (SABS), Bolt Biotherapeutics (BOLT), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), and United Therapeutics (UTHR). These companies are all part of the "biotechnology" industry. Curis vs. Its Competitors Fortress Biotech SAB Biotherapeutics Bolt Biotherapeutics Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen United Therapeutics Fortress Biotech (NASDAQ:FBIO) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability. Does the media favor FBIO or CRIS? In the previous week, Fortress Biotech had 1 more articles in the media than Curis. MarketBeat recorded 2 mentions for Fortress Biotech and 1 mentions for Curis. Curis' average media sentiment score of 1.87 beat Fortress Biotech's score of 0.94 indicating that Curis is being referred to more favorably in the news media. Company Overall Sentiment Fortress Biotech Positive Curis Very Positive Do insiders and institutionals believe in FBIO or CRIS? 96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 30.0% of Curis shares are held by institutional investors. 27.9% of Fortress Biotech shares are held by insiders. Comparatively, 5.5% of Curis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is FBIO or CRIS more profitable? Fortress Biotech has a net margin of -71.24% compared to Curis' net margin of -376.08%. Curis' return on equity of 0.00% beat Fortress Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Fortress Biotech-71.24% -4,712.53% -27.67% Curis -376.08%N/A -97.14% Do analysts prefer FBIO or CRIS? Fortress Biotech currently has a consensus target price of $21.00, suggesting a potential upside of 965.99%. Curis has a consensus target price of $17.00, suggesting a potential upside of 823.91%. Given Fortress Biotech's higher probable upside, analysts plainly believe Fortress Biotech is more favorable than Curis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fortress Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Curis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, FBIO or CRIS? Fortress Biotech has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500. Comparatively, Curis has a beta of 3.6, meaning that its share price is 260% more volatile than the S&P 500. Which has stronger earnings & valuation, FBIO or CRIS? Curis has lower revenue, but higher earnings than Fortress Biotech. Fortress Biotech is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFortress Biotech$57.67M1.01-$46M-$2.23-0.88Curis$10.91M1.76-$43.39M-$6.23-0.30 SummaryFortress Biotech beats Curis on 9 of the 15 factors compared between the two stocks. Get Curis News Delivered to You Automatically Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRIS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRIS vs. The Competition Export to ExcelMetricCurisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.25M$3.05B$5.70B$9.50BDividend YieldN/A2.37%4.58%4.01%P/E Ratio-0.3021.3228.4120.08Price / Sales1.76285.38432.3189.32Price / CashN/A42.7636.2258.56Price / Book-2.598.378.675.88Net Income-$43.39M-$55.19M$3.25B$258.89M7 Day Performance2.22%5.86%4.25%3.71%1 Month Performance-17.12%17.29%10.51%11.72%1 Year Performance-69.93%4.39%35.68%18.01% Curis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRISCuris2.5717 of 5 stars$1.84flat$17.00+823.9%-69.4%$19.25M$10.91M-0.3060Positive NewsUpcoming EarningsFBIOFortress Biotech2.5057 of 5 stars$1.89-3.1%$21.00+1,011.1%-24.2%$57.66M$57.67M-0.85170SABSSAB Biotherapeutics3.6868 of 5 stars$2.70+5.1%$13.25+390.7%-7.6%$23.87M$1.32M-0.73140News CoverageAnalyst ForecastAnalyst RevisionGap UpHigh Trading VolumeBOLTBolt Biotherapeutics2.7101 of 5 stars$5.74+3.8%$50.00+771.1%-57.1%$10.60M$7.69M-0.1790Positive NewsHigh Trading VolumeAMGNAmgen4.3994 of 5 stars$295.87+0.4%$308.32+4.2%-8.3%$158.49B$33.42B27.0028,000Positive NewsAnalyst ForecastGILDGilead Sciences4.886 of 5 stars$108.28+0.1%$111.38+2.9%+51.9%$134.62B$28.75B13.9817,600Trending NewsAnalyst UpgradeVRTXVertex Pharmaceuticals4.3258 of 5 stars$458.49-0.3%$511.71+11.6%-4.6%$118.08B$11.02B0.006,100Positive NewsAnalyst RevisionREGNRegeneron Pharmaceuticals4.8248 of 5 stars$545.53+0.6%$814.57+49.3%-47.1%$58.57B$14.20B14.2215,106Trending NewsUpcoming EarningsAnalyst ForecastALNYAlnylam Pharmaceuticals4.0718 of 5 stars$320.520.0%$347.75+8.5%+38.2%$41.79B$2.25B-153.362,230News CoveragePositive NewsUpcoming EarningsBIIBBiogen4.8068 of 5 stars$122.68-1.8%$186.37+51.9%-42.2%$18.31B$9.68B12.117,605Upcoming EarningsAnalyst RevisionUTHRUnited Therapeutics4.9902 of 5 stars$293.12+0.4%$383.08+30.7%-9.5%$13.17B$2.88B11.651,305Trending NewsUpcoming EarningsInsider TradeAnalyst Revision Related Companies and Tools Related Companies Fortress Biotech Competitors SAB Biotherapeutics Competitors Bolt Biotherapeutics Competitors Amgen Competitors Gilead Sciences Competitors Vertex Pharmaceuticals Competitors Regeneron Pharmaceuticals Competitors Alnylam Pharmaceuticals Competitors Biogen Competitors United Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRIS) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Curis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Curis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
